Accessibility StatementSkip Navigation PHILADELPHIA, Oct. 1, 2025 /PRNewswire/ -- The law firm of Kaskela Law LLC announces that it is investigating the shareholder buyout offer made to STAAR Surgical Company (NASDAQ: STAA) ("STAAR" or the "Company") investors to determine whether the proposal is fair and provides sufficient monetary consideration for the Company's investors. Following the proposed transaction, STAAR shares will no longer be publicly traded. Click here to request additional information ab ...

GENEVA & LAKE FOREST, Calif.--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: STAA) ("STAAR†), the manufacturer of the Implantable Collamer® Lens (ICL), today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in connection with Alcon's acquisition of STAAR, expired at 11:59 p.m. ET on September 29, 2025. As previously announced,. ...

Group 1 - Halper Sadeh LLC is investigating STAAR Surgical Company for potential violations related to its sale to Alcon at $28.00 per share in cash [1] - CyberArk Software Ltd. is being investigated for its sale to Palo Alto Networks for $45.00 in cash and 2.2005 shares of Palo Alto common stock for each CyberArk share [2] - The firm may seek increased consideration for shareholders and additional disclosures regarding the proposed transactions [3] Group 2 - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options at no charge [4] - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [4]

Core Viewpoint - Kaskela Law LLC is investigating the fairness of the proposed buyout of STAAR Surgical Company by Alcon at a price of $28.00 per share, which is significantly lower than the company's recent trading prices and 52-week high [1][3]. Group 1: Buyout Details - On August 5, 2025, STAAR announced its agreement to be acquired by Alcon for $28.00 per share in cash [2]. - Many STAAR shareholders purchased their shares at prices above $30.00, indicating potential dissatisfaction with the buyout price [2]. Group 2: Investigation Focus - The investigation aims to determine if STAAR investors are receiving adequate monetary consideration for their shares [3]. - It will also assess whether the company's officers or directors breached their fiduciary duties or violated securities laws in agreeing to the buyout price [3]. Group 3: Shareholder Impact - The proposed buyout price of $28.00 per share is notably lower than STAAR's 52-week high of $38.60 per share, raising concerns among investors [3].

Core Insights - STAAR Surgical Company, a leader in phakic IOLs, announced the expiration of the 45-day "window shop" period related to its merger agreement with Alcon, with no competing acquisition proposals received [1] Company Summary - STAAR Surgical Company specializes in the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction [1] - The merger agreement with Alcon affiliates remains intact following the expiration of the "window shop" period [1] Industry Context - The expiration of the "window shop" period indicates a stable environment for STAAR Surgical's merger with Alcon, suggesting confidence in the deal's progression [1]

Core Viewpoint - Yunqi Capital, a 5.1% shareholder of Staar Surgical Company, opposes the proposed sale of the company to Alcon based on the terms announced on August 5 [1] Group 1 - Yunqi Capital believes the sale price of $28 per share is inadequate [1]

Core Viewpoint - Yunqi Capital Limited, a 5.1% shareholder of STAAR Surgical Company, opposes the proposed sale of STAAR to Alcon Inc. on the terms announced on August 5, 2025 [1] Group 1 - Yunqi Capital has released an open letter to fellow STAAR shareholders detailing the reasons for its opposition to the transaction [1]

In conjunction with the definitive proxy filing, Staar (STAA) is mailing the following letter to Staar stockholders: “On August 5, 2025, we announced that STAAR Surgical Company entered into a definitive merger agreement to be acquired by Alcon (ALC) for $28.00 per share in cash. STAAR will hold a virtual Special Meeting of Stockholders on October 23 at 8:30 a.m. to ask for your vote to adopt the merger agreement. The STAAR Board of Directors unanimously determined that the proposed merger with Alcon is in ...

Core Viewpoint - The Ademi Firm is investigating STAAR for potential breaches of fiduciary duty and other legal violations related to its transaction with Alcon Inc, where STAAR shareholders will receive $28 per share in cash, valuing the transaction at approximately $[1] Group 1 - The investigation by the Ademi Firm focuses on possible breaches of fiduciary duty by STAAR in its dealings with Alcon Inc [1] - Shareholders of STAAR are set to receive $28 per share in cash as part of the transaction [1] - The total valuation of the transaction is approximately $[1]

Core Insights - The article highlights the ongoing high activity in mergers and acquisitions (M&A) within the global medical device sector in 2025, driven by technology, cross-regional expansion, and supply chain integration [2][5][56] Group 1: M&A Trends and Key Transactions - In 2025, significant M&A activities are observed, including a $17.5 billion acquisition by Waters of BD Life Sciences, which aims to create a comprehensive diagnostic platform [29][32] - Alcon has been particularly active in the ophthalmology sector, completing multiple acquisitions to strengthen its full-chain capabilities from surgical to non-surgical solutions [5][6][11] - The cardiovascular and neuro-interventional sectors are seeing a shift towards less invasive treatments and diversified therapeutic approaches, including non-drug solutions [12][30] Group 2: Sector-Specific Insights - The ophthalmology market is experiencing increased concentration, with Alcon's strategy focusing on a comprehensive technology loop covering refractive surgery, cataracts, retinal diseases, and corneal regeneration [5][11] - The cardiovascular and neuro-interventional M&A activities are characterized by a focus on reducing trauma and recovery time, with innovations like ultrasound renal denervation and non-drug thrombectomy gaining traction [12][30] - The production and supply chain capabilities are being enhanced through acquisitions of key components and materials, which are crucial for maintaining delivery reliability and optimizing profit structures [20][31] Group 3: AI and Precision Diagnostics - The AI and precision diagnostics segment is witnessing strategic acquisitions that enhance high-margin business lines and clinical authority, with notable transactions like Waters acquiring BD [28][32] - The integration of AI technologies into clinical applications is progressing, with companies focusing on data assets and algorithm platforms to enhance diagnostic accuracy and market competitiveness [44][55] Group 4: Women's Health and Specialty Surgery - The women's health and specialty surgery sectors are characterized by high margins and strong brand reliance, with acquisitions focusing on specific surgical pathways that are difficult to replace [37][43] - Companies like Hologic are expanding their portfolios to cover the entire patient journey from diagnosis to treatment, enhancing customer loyalty and repeat business [42][56] Group 5: Future Outlook and Strategic Implications - The M&A landscape in 2025 reflects a strategic repositioning of companies to adapt to clinical trends and market demands, with a focus on comprehensive coverage of treatment pathways and supply chain security [53][55] - The article emphasizes the importance of aligning technology and market positioning early to capitalize on potential acquisition opportunities and achieve high valuations [55][56]